Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
CTI BioPharma Corp.
Seattle, Washington, United Statesctibiopharma.com ↗
- Ownership
- Private
- Employees
- ~128
- Development stage
- Other
01
Overview
CTI BioPharma developed and commercialized VONJO (pacritinib), an oral kinase inhibitor approved by the FDA in February 2022 for the treatment of adult patients with myelofibrosis with severe thrombocytopenia.
- Therapeutic areas
- HematologyImmunologyOncology
- Modalities
- Small molecule drugsOral kinase inhibitors
- Industry
- Biotech
02
Partnerships
Teva Pharmaceutical Industries Ltd.S*BIO Pte Ltd.Baxalta
Beyond the preview
Go deeper on CTI BioPharma Corp..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CTI BioPharma Corp..